價(jià)格 | ¥289 | ¥448 | ¥913 |
包裝 | 1mg | 2mg | 5mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:化合物 Afuresertib | 英文名稱:Afuresertib |
CAS:1047644-62-1 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.17% | 產(chǎn)品類別: 抑制劑 |
貨號: T1911 |
名稱 | Afuresertib |
描述 | Afuresertib (GSK2110183) is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. |
細(xì)胞實(shí)驗(yàn) | A 3-day proliferation assay using CellTiter-Glo is performed to measure the growth inhibition by the compounds at 0-30 μM. Cell growth is determined relative to untreated (DMSO) controls. EC50's are calculated from inhibition curves using a 4- or 6-parameter fitting algorithm in the Assay Client application.(Only for Reference) |
激酶實(shí)驗(yàn) | Potency (Ki*) of afuresertib: The true potency (Ki*) of the inhibitor is initially determined at low enzyme concentrations (0.1 nM AKT1, 0.7 nM AKT2, and 0.2 nM AKT3) using a filter binding assay and then confirmed with progress curve analysis. In the filter binding assay, a pre-mix of enzyme plus inhibitor is incubated for 1 h and then added to a GSKα peptide (Ac-KKGGRARTSS-FAEPG-amide) and [γ33P] ATP. Reactions are terminated after 2 h and the radio labeled AKT peptide product is captured in a phospho-cellulose filter plate. Progress curve analysis utilizes continuous real-time fluorescence detection of product formation using the Sox-AKT-tide substrate (Ac-ARKRERAYSF-d-Pro-Sox-Gly-NH2). |
體外活性 | 用10,30和100 mg/kg Afuresertib處理負(fù)荷SKOV3卵巢腫瘤異種移植物的小鼠,分別導(dǎo)致凝血酶形成指數(shù)為23%,37%和97%.每天給負(fù)荷BT474乳腺腫瘤異種移植物的小鼠,口服10,30或100 mg/kg Afuresertib,分別導(dǎo)致凝血酶形成指數(shù)為8%,37%和61%. |
體內(nèi)活性 | 總體上65%的血液學(xué)細(xì)胞系對Afuresertib敏感,EC50 < 1 μM。在測試的實(shí)體腫瘤細(xì)胞系中,21%對Afuresertib的EC50 <1 μM。Afuresertib抑制E17K AKT1突變蛋白的激酶活性,EC50為0.2 nM。Afuresertib顯示對多種AKT底物磷酸化水平(包括GSK3b,PRAS40,FOXO和胱天蛋白酶9)的濃度依賴性效應(yīng)。 |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 50 mg/mL (117.01 mM) Ethanol : 79 mg/mL (184.9 mM) |
關(guān)鍵字 | ROK | Rho-associated kinase | Rho-kinase | Inhibitor | Rho-associated protein kinase | Akt | GSK-2110183 | inhibit | PKC | PKB | GSK 2110183 | Protein kinase C | Afuresertib | ROCK | Protein kinase B |
相關(guān)產(chǎn)品 | Y-27632 dihydrochloride | Honokiol | Mitoxantrone dihydrochloride | Artemisinin | Darovasertib | Staurosporine | α-Vitamin E | Y-27632 | 2,3-Butanediol | RKI-1447 | Ethyl gallate | Thiazovivin |
相關(guān)庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 已知活性化合物庫 | 激酶抑制劑庫 | 抗衰老化合物庫 | TGF-β/Smad靶點(diǎn)化合物庫 | 藥物功能重定位化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP6年
|
上海澤葉生物科技有限公司
|
2025-02-24 | |
¥3500 |
VIP1年
|
本溪市佳宜生物商貿(mào)有限公司
|
2024-12-30 | |
¥7311.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |